Payment overview · 2025
General Payments
$1,029.90
57 reported records · 22 companies
Healthcare provider profile · identity verified
Jodi A Conley, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · GRAYSON, KY · NPI 1891860599
Verified facts
What the public records show
CMS Open Payments records show Jodi A Conley, PA received $1,029.90 in general payments during 2025 across 57 reported records.
Novo Nordisk Inc accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $160.28 | 15.6% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $155.37 | 15.1% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $135.43 | 13.2% | 9 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $82.10 | 8.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.24 | 5.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.53 | 4.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.10 | 3.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $36.78 | 3.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $35.79 | 3.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.91 | 3.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.07 | 3.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.16 | 2.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.67 | 2.4% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $21.02 | 2.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.14 | 2.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.05 | 1.9% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $19.14 | 1.9% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.14 | 1.9% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $19.00 | 1.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.84 | 1.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.31 | 1.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.83 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,029.90 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $144.79 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $135.43 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $89.99 | 4 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $82.10 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.29 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $70.29 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.53 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.10 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $35.79 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $34.97 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.91 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.16 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| VPRIV Normalized: vpriv |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $10.58 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $10.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
76 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 25 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 580 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 502 | 143 |
| Potassium Chloride | Potassium Chloride | 493 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 472 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 432 | 104 |
| Omeprazole | Omeprazole | 431 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 396 | 103 |
| Tramadol Hcl | Tramadol Hcl | 393 | 87 |
| Furosemide | Furosemide | 381 | 107 |
| Losartan Potassium | Losartan Potassium | 369 | 84 |
| Montelukast Sodium | Montelukast Sodium | 369 | 80 |
| Meloxicam | Meloxicam | 354 | 100 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 347 | 97 |
| Prednisone | Prednisone | 308 | 190 |
| Metoprolol Tartrate | Metoprolol Tartrate | 306 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 289 | 68 |
| Simvastatin | Simvastatin | 267 | 64 |
| Famotidine | Famotidine | 258 | 72 |
| Lisinopril | Lisinopril | 242 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 237 | 71 |
| Metformin Hcl | Metformin Hcl | 218 | 64 |
| Tizanidine Hcl | Tizanidine Hcl | 209 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 50 |
| Carvedilol | Carvedilol | 205 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 189 | 76 |
| Januvia | Sitagliptin Phosphate | 171 | 37 |
| Buspirone Hcl | Buspirone Hcl | 158 | 51 |
| Glipizide | Glipizide | 156 | 40 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 153 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 149 | 109 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 32 |
| Methocarbamol | Methocarbamol | 143 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 140 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 136 | 42 |
| Sertraline Hcl | Sertraline Hcl | 136 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 130 | 27 |
| Trazodone Hcl | Trazodone Hcl | 123 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 36 |
| Bupropion Xl | Bupropion Hcl | 109 | 26 |
| Lorazepam | Lorazepam | 99 | 24 |
| Ozempic | Semaglutide | 99 | 21 |
| Clonazepam | Clonazepam | 98 | 12 |
| Eliquis | Apixaban | 96 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 19 |
| Alprazolam | Alprazolam | 90 | 13 |
| Meclizine Hcl | Meclizine Hcl | 90 | 29 |
| Pregabalin | Pregabalin | 89 | 16 |
| Valsartan | Valsartan | 89 | 21 |
| Azithromycin | Azithromycin | 87 | 70 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 86 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 81 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 40 |
| Metformin Hcl Er | Metformin Hcl | 80 | 22 |
| Baclofen | Baclofen | 79 | 18 |
| Mirtazapine | Mirtazapine | 79 | 16 |
| Warfarin Sodium | Warfarin Sodium | 79 | suppressed |
| Ezetimibe | Ezetimibe | 78 | 22 |
| Fenofibrate | Fenofibrate,micronized | 78 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 18 |
| Synthroid | Levothyroxine Sodium | 76 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 16 |
| Celecoxib | Celecoxib | 72 | 19 |
| Donepezil Hcl | Donepezil Hcl | 71 | 16 |
| Mounjaro | Tirzepatide | 70 | 12 |
| Cephalexin | Cephalexin | 67 | 54 |
| Spironolactone | Spironolactone | 67 | 20 |
| Sucralfate | Sucralfate | 67 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 18 |
| Azelastine Hcl | Azelastine Hcl | 65 | 37 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 12 |
| Allopurinol | Allopurinol | 58 | 17 |
| Estradiol | Estradiol | 57 | 19 |
| Glipizide Er | Glipizide | 56 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 17 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 55 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 12 |
| Cefdinir | Cefdinir | 48 | 39 |
| Levetiracetam | Levetiracetam | 48 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 21 |
| Fluconazole | Fluconazole | 46 | 26 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | 11 |
| Atenolol | Atenolol | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 18 |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 38 |
| Topiramate | Topiramate | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 13 |
| Clonidine Hcl | Clonidine Hcl | 39 | 16 |
| Glimepiride | Glimepiride | 39 | 11 |
| Linzess | Linaclotide | 39 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 12 |
| Rybelsus | Semaglutide | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 14 |
| Jardiance | Empagliflozin | 34 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 30 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 13 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 27 |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | 13 |
| Nystatin | Nystatin | 27 | 22 |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | 13 |
| Diazepam | Diazepam | 24 | 11 |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | 11 |
| Calcitriol | Calcitriol | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Mupirocin | Mupirocin | 14 | suppressed |
| Oxazepam | Oxazepam | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,029.90 · 57 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, AUSTEDO XR, BEVESPI AEROSPHERE, BREZTRI, CAPLYTA, Cologuard Collection Kit, DUPIXENT, Dexcom G6 Transmitter, Hillrom - Vest System Model 105 Home Care, Jornay PM, Korlym, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, Prolastin-C Liquid, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, VPRIV, VRAYLAR, Vest Therapy Und, WAKIX, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error